Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia

@article{Phan2010AdjuvantTT,
  title={Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia},
  author={Ngoc Quan Phan and Dorothee Siepmann and Ingrid Gralow and Sonja St{\"a}nder},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year={2010},
  volume={8}
}
Background: Postherpetic neuralgia is a frequent adverse event in herpes zoster patients and difficult to treat. Conventional analgetic therapy often fails to reduce the burning pain transmitted by unmyelinated nerve fibers. These nerves express cannabinoid receptors which exert a role in modulation of nociceptive symptoms. Therefore, topical therapy with cannabinoid receptor agonist seems likely to suppress local burning pain. 
Cannabinoids and muscular pain. Effectiveness of the local administration in rat
TLDR
The effects of CB receptor agonists in muscular pain have hardly been studied and the use of cannabis derivatives has been recently accepted as a useful alternative for the treatment of spasticity and pain in patients with multiple sclerosis.
Pain Management of Herpes Zoster
TLDR
Further efforts are needed to minimize pain of the patients suffering from HZ and PHN as it affects the quality of life in the aspect of both physical and psychological impairments.
Neuropathic itch treated with oral cannabinoids: A case series
Cannabinoids and muscular pain. Effectiveness of the local administration in rat
TLDR
Evidence is provided that both, CB 1 and CB 2 receptors can contribute to muscular antinociception and, interestingly, suggest that the local administration of CB agonists could be a new and useful pharmacological strategy in the treatment of muscular pain, avoiding adverse effects induced by systemic administration.
Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications
TLDR
This two-part series discusses specific therapies, local anesthetics, and other drugs, as well as how a clinician might use specific aspects of a patient’s neuropathic pain presentation to help guide them in the selection of a topical agent.
Evaluation of chronic pruritus in older patients
TLDR
A rational work-up adapted to the special premises and needs of geriatric patients is presented, which may facilitate the choice of suitable therapeutic regimens.
Chronic Pruritus: Current and Emerging Treatment Options
TLDR
Basic measures such as emollients to avoid xerosis and treatment of the underlying disease should be initiated regardless of the duration of the symptom, and new insights into pathways involved in the development and maintenance of chronic pruritus have led to a considerable number of novel antipruritic drugs.
A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation
TLDR
There is a significant lack of evidence indicating that cannabinoids administered by routes other than oral or inhaled may be an effective alternative, with better tolerance and safety in the treatment of neuropathic pain.
Topical cannabinoids in dermatology.
TLDR
The studies of topical cannabinoids in skin conditions and their current place in dermatology practice are reviewed.
New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoyletha- nolamide
Persistent pain in neuropathic conditions is often quite refractory to conventional analgesic therapy, with most patients obtaining, at best, only partial relief of symptoms. The tendency still
...
...

References

SHOWING 1-10 OF 33 REFERENCES
[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].
TLDR
Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins and may be even more effective with broader indications.
Postherpetic neuralgia: epidemiology, pathophysiology and management
TLDR
The incidence of HZ, and therefore that of PHN, is likely to increase as a result of greater longevity and increasing numbers of patients receiving treatment that compromises cell-mediated immunity.
Topical lidocaine for the treatment of postherpetic neuralgia.
TLDR
There is insufficient evidence to recommend topical lidocaine as a first-line agent in the treatment of postherpetic neuralgia with allodynia, and the authors suggest that the sample had been contaminated during the assay procedure.
A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.
TLDR
It is concluded that capsaicin 0.075% cream is a safe and effective treatment for the pain of postherpetic neuralgia and should be considered for initial management of patients with this condition.
Neurophysiology of pruritus: cutaneous elicitation of itch.
TLDR
Investigations have revealed new receptor systems on cutaneous sensory nerve fibers that may modulate itch and thereby represent targets for antipruritic therapy, including neurotransmitters, neuropeptides, and inflammatory mediators.
Management of herpes zoster (shingles) and postherpetic neuralgia
TLDR
Herpes zoster (HZ) results from recrudescence of varicella zoster virus latent since primary infection (varicella), and postherpetic neuralgia (PHN), defined as significant pain or dysaesthesia present ≥ 3 months after HZ is the most common complication.
Mode of action of cannabinoids on nociceptive nerve endings
TLDR
The cannabinoid receptor family currently includes two cloned metabotropic receptors: CB1, CB2 and possibly GPR55 which are distributed widely across many key loci in pain-modulating pathways, including the peripheral terminals of primary afferents.
Herpes zoster itch: preliminary epidemiologic data.
Chronic itch and pain—Similarities and differences
...
...